Dianthus Therapeutics (NASDAQ:DNTH) Announces Quarterly Earnings Results

Posted by Stanley Muller on Aug 4th, 2026

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05), FiscalAI reports. The firm had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%.

Dianthus Therapeutics Stock Up 4.6%

Shares of DNTH traded up $4.89 during trading on Tuesday, reaching $110.92. The company’s stock had a trading volume of 636,619 shares, compared to its average volume of 947,686. The company has a fifty day moving average of $93.50 and a two-hundred day moving average of $79.50. Dianthus Therapeutics has a twelve month low of $18.08 and a twelve month high of $114.55. The company has a market cap of $6.06 billion, a price-to-earnings ratio of -26.86 and a beta of 1.22.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on DNTH. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wedbush boosted their price objective on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Finally, TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Dianthus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $117.82.

View Our Latest Research Report on Dianthus Therapeutics

Insider Activity

In related news, EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction on Monday, June 1st. The shares were sold at an average price of $90.62, for a total value of $2,404,148.60. Following the completion of the sale, the executive vice president owned 4,000 shares in the company, valued at approximately $362,480. The trade was a 86.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Adam M. Veness sold 30,000 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the completion of the sale, the senior vice president directly owned 30,000 shares in the company, valued at $2,424,000. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 87,779 shares of company stock worth $7,985,235. 3.02% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. increased its position in shares of Dianthus Therapeutics by 125.9% in the 4th quarter. Invesco Ltd. now owns 101,489 shares of the company’s stock worth $4,182,000 after purchasing an additional 56,560 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Dianthus Therapeutics during the fourth quarter worth about $550,000. Voloridge Investment Management LLC grew its stake in Dianthus Therapeutics by 80.5% in the fourth quarter. Voloridge Investment Management LLC now owns 39,480 shares of the company’s stock worth $1,627,000 after purchasing an additional 17,612 shares in the last quarter. Virtus Investment Advisers LLC grew its stake in Dianthus Therapeutics by 7.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock worth $260,000 after purchasing an additional 416 shares in the last quarter. Finally, SummitTX Capital L.P. bought a new stake in Dianthus Therapeutics in the fourth quarter valued at about $3,623,000. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

(Get Free Report)

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.